Clinical Trials
- Brain and Other Nervous System Cancers
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
- GenderBoth
- Date08/05/2020
- Brain and Other Nervous System Cancers
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
- Date07/15/2020
- Brain and Other Nervous System Cancers
Genomically-Guided Treatment Trial in Brain Metastases
- Ages18 years and older
- GenderBoth
- Date02/10/2020
- Bladder Cancer, Brain and Other Nervous System Cancers, Breast Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Leukemia, Lymphoma, and Myeloma, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
- Ages18 years and older
- GenderBoth
- Date08/07/2016
- Brain and Other Nervous System Cancers
Phase 1: BGB-290 in combination with TMZ in patients w/ IDH1/2-mutant WHO grade II-IV recurrent glioma: Phase 2: Grade II-III patients in will be stratified into 2 arms based on the timing of prior alkylator chemotherapy exposure; a third arm will include the subset of glioblastoma (grade IV) patients
- Date07/15/2020
- Brain and Other Nervous System Cancers
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
- Ages18 years and older
- GenderBoth
- Date10/27/2019
- Brain and Other Nervous System Cancers
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
- Ages18 years and older
- GenderBoth
- Date12/26/2016
- Brain and Other Nervous System Cancers
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
- Date05/22/2019